These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 21550404)
41. A novel conditional Sgsh knockout mouse model recapitulates phenotypic and neuropathic deficits of Sanfilippo syndrome. Lau AA; King BM; Thorsen CL; Hassiotis S; Beard H; Trim PJ; Whyte LS; Tamang SJ; Duplock SK; Snel MF; Hopwood JJ; Hemsley KM J Inherit Metab Dis; 2017 Sep; 40(5):715-724. PubMed ID: 28451919 [TBL] [Abstract][Full Text] [Related]
42. Novel treatments and future perspectives: outcomes of intrathecal drug delivery. Dickson PI Int J Clin Pharmacol Ther; 2009; 47 Suppl 1():S124-7. PubMed ID: 20040323 [TBL] [Abstract][Full Text] [Related]
43. Gastrointestinal pathology in a mouse model of mucopolysaccharidosis type IIIA. Roberts AL; Howarth GS; Liaw WC; Moretta S; Kritas S; Lymn KA; Yazbeck R; Tran C; Fletcher JM; Butler RN; Byers S J Cell Physiol; 2009 May; 219(2):259-64. PubMed ID: 19170061 [TBL] [Abstract][Full Text] [Related]
44. Chemically modified recombinant human sulfamidase (SOBI003) in mucopolysaccharidosis IIIA patients: Results from an open, non-controlled, multicenter study. Harmatz P; Muenzer J; Ezgü F; Dalén P; Huledal G; Lindqvist D; Gelius SS; Wikén M; Önnestam K; Bröijersén A Mol Genet Metab; 2022 Aug; 136(4):249-259. PubMed ID: 35835061 [TBL] [Abstract][Full Text] [Related]
45. High and prolonged sulfamidase secretion by the liver of MPS-IIIA mice following hydrodynamic tail vein delivery of antibiotic-free pFAR4 plasmid vector. Quiviger M; Arfi A; Mansard D; Delacotte L; Pastor M; Scherman D; Marie C Gene Ther; 2014 Dec; 21(12):1001-7. PubMed ID: 25142140 [TBL] [Abstract][Full Text] [Related]
46. Robust LC-MS/MS methods for analysis of heparan sulfate levels in CSF and brain for application in studies of MPS IIIA. Makower Å; Arnelöf E; Andersson T; Edlund PO; Gustavsson S; Janson J; Gelius SS; Tjernberg A Bioanalysis; 2019 Aug; 11(15):1389-1403. PubMed ID: 31490106 [No Abstract] [Full Text] [Related]
47. Embryonic stem cell-derived glial precursors as a vehicle for sulfamidase production in the MPS-IIIA mouse brain. Robinson AJ; Zhao G; Rathjen J; Rathjen PD; Hutchinson RG; Eyre HJ; Hemsley KM; Hopwood JJ Cell Transplant; 2010; 19(8):985-98. PubMed ID: 20350350 [TBL] [Abstract][Full Text] [Related]
49. Sanfilippo syndrome in Turkey: Identification of novel mutations in subtypes A and B. Emre S; Terzioglu M; Tokatli A; Coskun T; Ozalp I; Weber B; Hopwood JJ Hum Mutat; 2002 Feb; 19(2):184-5. PubMed ID: 11793481 [TBL] [Abstract][Full Text] [Related]
50. Sulfamidase deficiency in a family of Dachshunds: a canine model of mucopolysaccharidosis IIIA (Sanfilippo A). Fischer A; Carmichael KP; Munnell JF; Jhabvala P; Thompson JN; Matalon R; Jezyk PF; Wang P; Giger U Pediatr Res; 1998 Jul; 44(1):74-82. PubMed ID: 9667374 [TBL] [Abstract][Full Text] [Related]
51. N-butyldeoxynojirimycin treatment restores the innate fear response and improves learning in mucopolysaccharidosis IIIA mice. Kaidonis X; Byers S; Ranieri E; Sharp P; Fletcher J; Derrick-Roberts A Mol Genet Metab; 2016 Jun; 118(2):100-10. PubMed ID: 27106513 [TBL] [Abstract][Full Text] [Related]
52. Fluoxetine ameliorates mucopolysaccharidosis type IIIA. Capuozzo A; Montefusco S; Cacace V; Sofia M; Esposito A; Napolitano G; Nusco E; Polishchuk E; Pizzo MT; De Risi M; De Leonibus E; Sorrentino NC; Medina DL Mol Ther; 2022 Apr; 30(4):1432-1450. PubMed ID: 35121108 [TBL] [Abstract][Full Text] [Related]
53. Inhibition of glycosaminoglycan synthesis using rhodamine B in a mouse model of mucopolysaccharidosis type IIIA. Roberts AL; Thomas BJ; Wilkinson AS; Fletcher JM; Byers S Pediatr Res; 2006 Sep; 60(3):309-14. PubMed ID: 16857766 [TBL] [Abstract][Full Text] [Related]
54. Correction of murine mucopolysaccharidosis type IIIA central nervous system pathology by intracerebroventricular lentiviral-mediated gene delivery. McIntyre C; Derrick-Roberts AL; Byers S; Anson DS J Gene Med; 2014; 16(11-12):374-87. PubMed ID: 25418946 [TBL] [Abstract][Full Text] [Related]
55. Open field locomotor activity and anxiety-related behaviors in mucopolysaccharidosis type IIIA mice. Lau AA; Crawley AC; Hopwood JJ; Hemsley KM Behav Brain Res; 2008 Aug; 191(1):130-6. PubMed ID: 18453006 [TBL] [Abstract][Full Text] [Related]
56. Development of motor deficits in a murine model of mucopolysaccharidosis type IIIA (MPS-IIIA). Hemsley KM; Hopwood JJ Behav Brain Res; 2005 Mar; 158(2):191-9. PubMed ID: 15698885 [TBL] [Abstract][Full Text] [Related]
57. Transport, enzymatic activity, and stability of mutant sulfamidase (SGSH) identified in patients with mucopolysaccharidosis type III A. Muschol N; Storch S; Ballhausen D; Beesley C; Westermann JC; Gal A; Ullrich K; Hopwood JJ; Winchester B; Braulke T Hum Mutat; 2004 Jun; 23(6):559-66. PubMed ID: 15146460 [TBL] [Abstract][Full Text] [Related]
58. A Preclinical Study Evaluating AAVrh10-Based Gene Therapy for Sanfilippo Syndrome. Winner LK; Beard H; Hassiotis S; Lau AA; Luck AJ; Hopwood JJ; Hemsley KM Hum Gene Ther; 2016 May; 27(5):363-75. PubMed ID: 26975339 [TBL] [Abstract][Full Text] [Related]
59. Differential subcellular localization of cholesterol, gangliosides, and glycosaminoglycans in murine models of mucopolysaccharide storage disorders. McGlynn R; Dobrenis K; Walkley SU J Comp Neurol; 2004 Dec; 480(4):415-26. PubMed ID: 15558784 [TBL] [Abstract][Full Text] [Related]
60. AAVrh10 Vector Corrects Disease Pathology in MPS IIIA Mice and Achieves Widespread Distribution of SGSH in Large Animal Brains. Hocquemiller M; Hemsley KM; Douglass ML; Tamang SJ; Neumann D; King BM; Beard H; Trim PJ; Winner LK; Lau AA; Snel MF; Gomila C; Ausseil J; Mei X; Giersch L; Plavsic M; Laufer R Mol Ther Methods Clin Dev; 2020 Jun; 17():174-187. PubMed ID: 31909089 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]